Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Vieito

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Magnetic Resonance Imaging : JMRI|June 19, 2024
Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRICarlos Macarro, Kinga Bernatowicz, Alonso Garcia-Ruiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Communications Medicine|November 20, 2025
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRIFrancesco Grussu, Athanasios Grigoriou, Kinga Bernatowicz, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterationsMarie Morfouace, Franck Bielle, Evangelia Razis, et al.
Communications Biology|November 26, 2025
Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim frameworkAthanasios Grigoriou, Carlos Macarro, Marco Palombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Neuro-Oncology Advances|November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastomaMaria Vieito, Matteo Simonelli, Filip de Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
NPJ Precision Oncology|January 6, 2026
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric studyOriol Mirallas, Fiorella Ruiz-Pace, Gabriel Velilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Magnetic Resonance Imaging : JMRI|June 19, 2024
Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRICarlos Macarro, Kinga Bernatowicz, Alonso Garcia-Ruiz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2019
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 CriteriaIgnacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, et al.
Communications Medicine|November 20, 2025
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRIFrancesco Grussu, Athanasios Grigoriou, Kinga Bernatowicz, et al.
European Journal of Cancer (Oxford, England : 1990)|May 20, 2025
Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterationsMarie Morfouace, Franck Bielle, Evangelia Razis, et al.
Communications Biology|November 26, 2025
Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim frameworkAthanasios Grigoriou, Carlos Macarro, Marco Palombo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Neuro-Oncology Advances|November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastomaMaria Vieito, Matteo Simonelli, Filip de Vos, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
NPJ Precision Oncology|January 6, 2026
Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric studyOriol Mirallas, Fiorella Ruiz-Pace, Gabriel Velilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With <i>BRAF</i> V600-Mutant Solid TumorsMaria Vieito, Elisa Fontana, Catherine H Han, et al.
Pageof 4